Skip to main content
MedPathMedPath Home
Clinical Trials/2023-508308-40-00
2023-508308-40-00
Active, not recruiting
Phase 3

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

Merck Sharp & Dohme LLC26 sites in 5 countries215 target enrollmentStarted: March 25, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Interventionspembrolizumab

Overview

Phase
Phase 3
Status
Active, not recruiting
Enrollment
215
Locations
26
Primary Endpoint
Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab at Cycle 1
OverviewEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

  1. To compare AUC between pembrolizumab SC vs pembrolizumab IV.
  2. To compare Ctrough between pembrolizumab SC vs pembrolizumab IV

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Has pathologically (histologically or cytologically) confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC)
  • •Has adequate organ function
  • •Has Stage IV (T any, N any, M1a, M1b, or M1c - American Joint Committee on Cancer 8th Edition) squamous or nonsquamous NSCLC
  • •Has confirmation that epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), or Receptor Tyrosine Kinase 1 (ROS1)-directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC. Participants with purely squamous NSCLC do not require testing
  • •Has not received prior systemic treatment for their metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease
  • •Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 or 1
  • •Male participants are eligible to participate if they agree to use contraception as per protocol unless confirmed to be azoospermic
  • •A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees of using a contraceptive method per protocol
  • •Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology
  • •Submit an archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated for PD-L1 status determination prior to randomization

Exclusion Criteria

  • •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • •Before the first dose of study intervention: a) Has received prior systemic cytotoxic chemotherapy for metastatic NSCLC b) Has received antineoplastic biological therapy for metastatic NSCLC c) Has had major surgery (<3 weeks prior to first dose) d) Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • •Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention
  • •Is expected to require any other form of antineoplastic therapy while on study
  • •For participants with nonsquamous histology: Is unable to interrupt aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period
  • •For participants with nonsquamous histology: Is unable or unwilling to take folic acid or vitamin B12 supplementation
  • •Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
  • •Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention
  • •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention

Arms & Interventions

pembrolizumab

Experimental

Participants receiving pembrolizumab

Intervention: pembrolizumab (Drug)

Outcomes

Primary Outcomes

Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab at Cycle 1

Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab at Cycle 1

Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab

Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab

Secondary Outcomes

  • Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
  • Observed Ctrough of Pembrolizumab at the End of Cycle 1
  • Maximum Concentration (Cmax) of Pembrolizumab at Cycle 1
  • AUC 0-3wks of Pembrolizumab at Cycle 6
  • Cmax of Pembrolizumab at Cycle 6
  • Observed Ctrough of Pembrolizumab at the End of Cycle 6
  • Number of Participants Who Experienced an Adverse Event (AE)
  • Number of Participants Who Discontinued Study Treatment Due to an AE
  • Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR
  • Overall Survival (OS)
  • Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR
  • Anti-Drug Antibodies (ADAs) Incidence After Administration of Pembrolizumab

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Sung Jin (Laura) Kim

Scientific

Merck Sharp & Dohme LLC

Study Sites (26)

Loading locations...

Similar Trials

Active, not recruiting
Phase 3
A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2024-512015-47-00Incyte Corp.42
Completed
Phase 3
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy
2022-501439-18-00Merck Sharp & Dohme LLC206
Not yet recruiting
Not Applicable
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
NCT07275216City of Hope Medical Center23
Recruiting
Phase 2
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)
2024-515646-16-00AGO Research GmbH42
Active, not recruiting
Phase 3
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma
2022-501966-23-00Merck Sharp & Dohme LLC530